{"pmid":32501145,"title":"Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).","text":["Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).","As observed in other infections with a systemic inflammatory response, severe COVID-19 is associated with hypercoagulability and a prothrombotic state. Currently, there is growing evidence that pulmonary embolism and thrombosis contribute to adverse outcomes and increased mortality in critically ill patients with COVID-19. The optimal thromboprophylactic regimen for patients with COVID-19 is not known. Whereas pharmacologic thromboprophylaxis is generally recommended for all hospitalized COVID-19 patients, adequate dosing of anticoagulants remains a controversial issue. Therefore, we summarize current evidence from the available literature and, on behalf of the German Society of Angiology (DGA), we aim to provide advice to establish an improved and more uniform strategy for thromboprophylaxis in patients with COVID-19.","Vasa","Linnemann, Birgit","Bauersachs, Rupert","Grebe, Mathias","Klamroth, Robert","Muller, Oliver","Schellong, Sebastian","Lichtenberg, Michael","32501145"],"abstract":["As observed in other infections with a systemic inflammatory response, severe COVID-19 is associated with hypercoagulability and a prothrombotic state. Currently, there is growing evidence that pulmonary embolism and thrombosis contribute to adverse outcomes and increased mortality in critically ill patients with COVID-19. The optimal thromboprophylactic regimen for patients with COVID-19 is not known. Whereas pharmacologic thromboprophylaxis is generally recommended for all hospitalized COVID-19 patients, adequate dosing of anticoagulants remains a controversial issue. Therefore, we summarize current evidence from the available literature and, on behalf of the German Society of Angiology (DGA), we aim to provide advice to establish an improved and more uniform strategy for thromboprophylaxis in patients with COVID-19."],"journal":"Vasa","authors":["Linnemann, Birgit","Bauersachs, Rupert","Grebe, Mathias","Klamroth, Robert","Muller, Oliver","Schellong, Sebastian","Lichtenberg, Michael"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32501145","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1024/0301-1526/a000885","keywords":["covid-19","d-dimers","thromboembolism","deep vein thrombosis","pulmonary embolism"],"topics":["Treatment"],"weight":1,"_version_":1668890966332801024,"score":9.490897,"similar":[{"pmid":32451823,"title":"Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.","text":["Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.","Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p < 0.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level < 1.0 microg/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level >/= 1.0 microg/ml and >/= 3 microg/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0 mug/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies.","J Thromb Thrombolysis","Artifoni, Mathieu","Danic, Gwenvael","Gautier, Giovanni","Gicquel, Pascal","Boutoille, David","Raffi, Francois","Neel, Antoine","Lecomte, Raphael","32451823"],"abstract":["Coagulopathy in COVID-19 is a burning issue and strategies to prevent thromboembolic events are debated and highly heterogeneous. The objective was to determine incidence and risk factors of venous thromboembolism (VTE) in COVID-19 inpatients receiving thromboprophylaxis. In this retrospective French cohort study, patients hospitalized in medical wards non-ICU with confirmed COVID-19 and adequate thromboprophylaxis were included. A systematic low limb venous duplex ultrasonography was performed at hospital discharge or earlier if deep venous thrombosis (DVT) was clinically suspected. Chest angio-CT scan was performed when pulmonary embolism (PE) was suspected. Of 71 patients, 16 developed VTE (22.5%) and 7 PE (10%) despite adequate thromboprophylaxis. D-dimers at baseline were significantly higher in patients with DVT (p < 0.001). Demographics, comorbidities, disease manifestations, severity score, and other biological parameters, including inflammatory markers, were similar in patients with and without VTE. The negative predictive value of a baseline D-dimer level < 1.0 microg/ml was 90% for VTE and 98% for PE. The positive predictive value for VTE was 44% and 67% for D-dimer level >/= 1.0 microg/ml and >/= 3 microg/ml, respectively. The association between D-dimer level and VTE risk increased by taking into account the latest available D-dimer level prior to venous duplex ultrasonography for the patients with monitoring of D-dimer. Despite thromboprophylaxis, the risk of VTE is high in COVID-19 non-ICU inpatients. Increased D-dimer concentrations of more than 1.0 mug/ml predict the risk of venous thromboembolism. D-dimer level-guided aggressive thromboprophylaxis regimens using higher doses of heparin should be evaluated in prospective studies."],"journal":"J Thromb Thrombolysis","authors":["Artifoni, Mathieu","Danic, Gwenvael","Gautier, Giovanni","Gicquel, Pascal","Boutoille, David","Raffi, Francois","Neel, Antoine","Lecomte, Raphael"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451823","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s11239-020-02146-z","keywords":["covid-19","d-dimer","pulmonary embolism","venous thromboembolism"],"locations":["French","thromboprophylaxis","thromboprophylaxis","heparin","thromboprophylaxis"],"countries":["France"],"countries_codes":["FRA|France"],"e_drugs":["Heparin"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667881798549372928,"score":225.67735},{"pmid":32304577,"title":"Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action.","text":["Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action.","Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy, namely disseminated intravascular coagulation, which has a rather prothrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in intensive care units appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present.","Br J Haematol","Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos","32304577"],"abstract":["Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated with coagulopathy, namely disseminated intravascular coagulation, which has a rather prothrombotic character with high risk of venous thromboembolism. The incidence of venous thromboembolism among COVID-19 patients in intensive care units appears to be somewhat higher compared to that reported in other studies including such patients with other disease conditions. D-dimer might help in early recognition of these high-risk patients and also predict outcome. Preliminary data show that in patients with severe COVID-19, anticoagulant therapy appears to be associated with lower mortality in the subpopulation meeting sepsis-induced coagulopathy criteria or with markedly elevated d-dimer. Recent recommendations suggest that all hospitalized COVID-19 patients should receive thromboprophylaxis, or full therapeutic-intensity anticoagulation if such an indication is present."],"journal":"Br J Haematol","authors":["Kollias, Anastasios","Kyriakoulis, Konstantinos G","Dimakakos, Evangelos","Poulakou, Garyphallia","Stergiou, George S","Syrigos, Konstantinos"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304577","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1111/bjh.16727","keywords":["sars-cov-2","anticoagulant","prophylaxis","thromboembolism","thrombosis"],"locations":["thromboprophylaxis"],"topics":["Treatment","Prevention"],"weight":1,"_version_":1666138491072806913,"score":204.13715},{"pmid":32381264,"pmcid":"PMC7192101","title":"Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.","text":["Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.","INTRODUCTION: We recently reported a high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three Dutch hospitals. In answering questions raised regarding our study, we updated our database and repeated all analyses. METHODS: We re-evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction and/or systemic arterial embolism in all COVID-19 patients admitted to the ICUs of 2 Dutch university hospitals and 1 Dutch teaching hospital from ICU admission to death, ICU discharge or April 22nd 2020, whichever came first. RESULTS: We studied the same 184 ICU patients as reported on previously, of whom a total of 41 died (22%) and 78 were discharged alive (43%). The median follow-up duration increased from 7 to 14 days. All patients received pharmacological thromboprophylaxis. The cumulative incidence of the composite outcome, adjusted for competing risk of death, was 49% (95% confidence interval [CI] 41-57%). The majority of thrombotic events were PE (65/75; 87%). In the competing risk model, chronic anticoagulation therapy at admission was associated with a lower risk of the composite outcome (Hazard Ratio [HR] 0.29, 95%CI 0.091-0.92). Patients diagnosed with thrombotic complications were at higher risk of all-cause death (HR 5.4; 95%CI 2.4-12). Use of therapeutic anticoagulation was not associated with all-cause death (HR 0.79, 95%CI 0.35-1.8). CONCLUSION: In this updated analysis, we confirm the very high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 pneumonia.","Thromb Res","Klok, F A","Kruip, M J H A","van der Meer, N J M","Arbous, M S","Gommers, D","Kant, K M","Kaptein, F H J","van Paassen, J","Stals, M A M","Huisman, M V","Endeman, H","32381264"],"abstract":["INTRODUCTION: We recently reported a high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 admitted to the intensive care units (ICUs) of three Dutch hospitals. In answering questions raised regarding our study, we updated our database and repeated all analyses. METHODS: We re-evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction and/or systemic arterial embolism in all COVID-19 patients admitted to the ICUs of 2 Dutch university hospitals and 1 Dutch teaching hospital from ICU admission to death, ICU discharge or April 22nd 2020, whichever came first. RESULTS: We studied the same 184 ICU patients as reported on previously, of whom a total of 41 died (22%) and 78 were discharged alive (43%). The median follow-up duration increased from 7 to 14 days. All patients received pharmacological thromboprophylaxis. The cumulative incidence of the composite outcome, adjusted for competing risk of death, was 49% (95% confidence interval [CI] 41-57%). The majority of thrombotic events were PE (65/75; 87%). In the competing risk model, chronic anticoagulation therapy at admission was associated with a lower risk of the composite outcome (Hazard Ratio [HR] 0.29, 95%CI 0.091-0.92). Patients diagnosed with thrombotic complications were at higher risk of all-cause death (HR 5.4; 95%CI 2.4-12). Use of therapeutic anticoagulation was not associated with all-cause death (HR 0.79, 95%CI 0.35-1.8). CONCLUSION: In this updated analysis, we confirm the very high cumulative incidence of thrombotic complications in critically ill patients with COVID-19 pneumonia."],"journal":"Thromb Res","authors":["Klok, F A","Kruip, M J H A","van der Meer, N J M","Arbous, M S","Gommers, D","Kant, K M","Kaptein, F H J","van Paassen, J","Stals, M A M","Huisman, M V","Endeman, H"],"date":"2020-05-09T11:00:00Z","year":2020,"_id":"32381264","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.thromres.2020.04.041","keywords":["covid-19","deep vein thrombosis","pulmonary embolism","stroke","venous thromboembolism"],"locations":["Dutch","Dutch","Dutch"],"countries":["Netherlands"],"countries_codes":["NLD|Netherlands"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666419683380690945,"score":199.965},{"pmid":32291094,"pmcid":"PMC7146714","title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19.","text":["Incidence of thrombotic complications in critically ill ICU patients with COVID-19.","INTRODUCTION: COVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation. Reports on the incidence of thrombotic complications are however not available. METHODS: We evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism in all COVID-19 patients admitted to the ICU of 2 Dutch university hospitals and 1 Dutch teaching hospital. RESULTS: We studied 184 ICU patients with proven COVID-19 pneumonia of whom 23 died (13%), 22 were discharged alive (12%) and 139 (76%) were still on the ICU on April 5th 2020. All patients received at least standard doses thromboprophylaxis. The cumulative incidence of the composite outcome was 31% (95%CI 20-41), of which CTPA and/or ultrasonography confirmed VTE in 27% (95%CI 17-37%) and arterial thrombotic events in 3.7% (95%CI 0-8.2%). PE was the most frequent thrombotic complication (n = 25, 81%). Age (adjusted hazard ratio (aHR) 1.05/per year, 95%CI 1.004-1.01) and coagulopathy, defined as spontaneous prolongation of the prothrombin time > 3 s or activated partial thromboplastin time > 5 s (aHR 4.1, 95%CI 1.9-9.1), were independent predictors of thrombotic complications. CONCLUSION: The 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is remarkably high. Our findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophylaxis towards high-prophylactic doses, even in the absence of randomized evidence.","Thromb Res","Klok, F A","Kruip, M J H A","van der Meer, N J M","Arbous, M S","Gommers, D A M P J","Kant, K M","Kaptein, F H J","van Paassen, J","Stals, M A M","Huisman, M V","Endeman, H","32291094"],"abstract":["INTRODUCTION: COVID-19 may predispose to both venous and arterial thromboembolism due to excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation. Reports on the incidence of thrombotic complications are however not available. METHODS: We evaluated the incidence of the composite outcome of symptomatic acute pulmonary embolism (PE), deep-vein thrombosis, ischemic stroke, myocardial infarction or systemic arterial embolism in all COVID-19 patients admitted to the ICU of 2 Dutch university hospitals and 1 Dutch teaching hospital. RESULTS: We studied 184 ICU patients with proven COVID-19 pneumonia of whom 23 died (13%), 22 were discharged alive (12%) and 139 (76%) were still on the ICU on April 5th 2020. All patients received at least standard doses thromboprophylaxis. The cumulative incidence of the composite outcome was 31% (95%CI 20-41), of which CTPA and/or ultrasonography confirmed VTE in 27% (95%CI 17-37%) and arterial thrombotic events in 3.7% (95%CI 0-8.2%). PE was the most frequent thrombotic complication (n = 25, 81%). Age (adjusted hazard ratio (aHR) 1.05/per year, 95%CI 1.004-1.01) and coagulopathy, defined as spontaneous prolongation of the prothrombin time > 3 s or activated partial thromboplastin time > 5 s (aHR 4.1, 95%CI 1.9-9.1), were independent predictors of thrombotic complications. CONCLUSION: The 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is remarkably high. Our findings reinforce the recommendation to strictly apply pharmacological thrombosis prophylaxis in all COVID-19 patients admitted to the ICU, and are strongly suggestive of increasing the prophylaxis towards high-prophylactic doses, even in the absence of randomized evidence."],"journal":"Thromb Res","authors":["Klok, F A","Kruip, M J H A","van der Meer, N J M","Arbous, M S","Gommers, D A M P J","Kant, K M","Kaptein, F H J","van Paassen, J","Stals, M A M","Huisman, M V","Endeman, H"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291094","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.thromres.2020.04.013","keywords":["covid-19","deep vein thrombosis","pulmonary embolism","stroke","thromboprophylaxis"],"locations":["Dutch","Dutch","CTPA"],"countries":["Netherlands"],"countries_codes":["NLD|Netherlands"],"topics":["Treatment"],"weight":1,"_version_":1666138494511087616,"score":197.35712},{"pmid":32374544,"title":"[Venous thrombotic risk related to SARS-CoV-2 : prevalence, recommendations and perspectives].","text":["[Venous thrombotic risk related to SARS-CoV-2 : prevalence, recommendations and perspectives].","Since the SARS-CoV-2 pandemic outbreak, growing evidence suggests that patients suffering from COVID-19 are at increased risk of thrombotic events. The sepsis-related activation of the coagulation combined with a high prevalence of common thrombotic risk factors could contribute to this prothrombotic state. Coagulation biomarkers could help in the identification of patients at risk of complications and mortality. The incidence of venous thromboembolic events appears to be increased, especially in severe COVID-19 patients. Based on that knowledge, several societies have provided recommendation on the prevention of venous thromboembolism. In this narrative review, we summarize available epidemiologic data on venous thromboembolism and recommendations on thromboprophylaxis in COVID-19.","Rev Med Suisse","Casini, Alessandro","Fontana, Pierre","Glauser, Frederic","Robert-Ebadi, Helia","Righini, Marc","Blondon, Marc","32374544"],"abstract":["Since the SARS-CoV-2 pandemic outbreak, growing evidence suggests that patients suffering from COVID-19 are at increased risk of thrombotic events. The sepsis-related activation of the coagulation combined with a high prevalence of common thrombotic risk factors could contribute to this prothrombotic state. Coagulation biomarkers could help in the identification of patients at risk of complications and mortality. The incidence of venous thromboembolic events appears to be increased, especially in severe COVID-19 patients. Based on that knowledge, several societies have provided recommendation on the prevention of venous thromboembolism. In this narrative review, we summarize available epidemiologic data on venous thromboembolism and recommendations on thromboprophylaxis in COVID-19."],"journal":"Rev Med Suisse","authors":["Casini, Alessandro","Fontana, Pierre","Glauser, Frederic","Robert-Ebadi, Helia","Righini, Marc","Blondon, Marc"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374544","source":"PubMed","week":"202019|May 04 - May 10","locations":["thromboprophylaxis"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1666138496341901312,"score":187.37401}]}